No influence of body weight on serum levels of antidepressants

Therapeutic Drug Monitoring

Volumn 33, Issue 6, 2011, Pages 730-734

  Unterecker, Stefan ^a   Deckert, Jürgen ^a   Pfuhlmann, Bruno ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Antidepressants; Dose corrected serum concentration; Influence of body weight; Therapeutic drug monitoring

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; DRUG METABOLITE; ESCITALOPRAM; NORCITALOPRAM; NORTRIPTYLINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; DRUG SCREENING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BODY MASS INDEX; BODY WEIGHT; COHORT STUDIES; DEPRESSION; DRUG MONITORING; FEMALE; HOSPITALS, PSYCHIATRIC; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT; RETROSPECTIVE STUDIES; THINNESS; YOUNG ADULT;

EID: 84856094691     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318237b0fa     Document Type: Article

References (24)

1. Asberg M, Crönholm B, Sjöqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J. 1971;3:331-334.
2. Bertilsson L, Mellström B, Sjökvist F, et al. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet. 1981;317:560-561. (Pubitemid 11130741)
3. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry. 1991;52:23-33.
4. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol. 2001;52:45S-54S. (Pubitemid 32823031)
5. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM Expert Group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265. (Pubitemid 39587052)
6. Hiemke C. Clinical utility of drug measurements and pharmacokinetics- therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol. 2008;64:159-166.
7. Hiemke C, Sachse J, Köller J, et al. HPLC with column-switching for therapeutic monitoring of psychoactive drugs. Clin Lab. 2003;27:26-27.
8. Hiemke C. Therapeutisches drug Monitoring von Antidepressiva und Neuroleptika. Methodische Voraussetzungen. Psychopharmakotherapie. 1995;2:21-23.
9. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52:5S-10S. (Pubitemid 32823027)
10. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau." Ther Drug Monit. 2006;26:145-151.
11. Blouin RA, Ensom MHH. Special pharmacokinetic considerations in the obese. In: Burton ME, Schentag JJ, Shaw LM, et al, eds. Applied Pharmacokinetics & Pharmacodynamics. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:231-241.
12. Uher R, Mors O, Hauser J, et al. Body weight as a predictor of antidepressant efficacy in the GENDEP project. J Affect Disord. 2009;118:147-154.
13. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999;37:8-19. (Pubitemid 29043392)
14. Pfuhlmann B, Gerlach M, Burger R, et al. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl. 2007;72:287-296.
15. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6-14. (Pubitemid 38067945)
16. Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res. 2007;55:81-95. (Pubitemid 46186037)
17. Jensen GL. Drug-induced hyperphagia: what can we learn from psychiatric medications? J Parenter Enteral Nutr. 2008;32:578-581.
18. Torrent C, Amann B, Sànchez-Moreno H, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118:4-18. (Pubitemid 351832022)
19. Uher R, Mors O, Hauser J, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol. 2011;14:367-375.
20. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007;62:321-326. (Pubitemid 47444280)
21. Papakostas GI, Petersen T, Iosifescu DV, et al. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005;8:59-63. (Pubitemid 40388814)
22. Khan A, Schwartz KA, Kolts RL, et al. BMI, sex, and antidepressant response. J Affect Disord. 2007;99:101-106. (Pubitemid 46275023)
23. Bies RR, Feng Y, Lotrich FE, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 2004;44:1352-1359. (Pubitemid 39518640)
24. Jin Y, Pollock BG, Frank E, et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol. 2010;50:62-72.